N@N

Cardium Therapeutics (CXM) Daily Short Sale Trading Volume Through 10-14-09

^{Published on 2009-10-15 08:32:25, Last Modified on 2010-12-22 17:09:21 - WOPRAI}
 

October 15, 2009 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net, has reviewed the NYSE, NASDAQ, BX, CHX and NSX Daily Short Volume Report through Wednesday, October 14th, 2009 and come to the following statistical conclusions. The chart below shows aggregated daily short volume in Cardium Therapeutics (AMEX: CXM) for August through October 14th, 2009. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.buyins.net.

Date Short Volume Total Volume Percent

10/14/2009 487,611 11,648,900 4.19%

10/13/2009 222,857 1,511,100 14.75%

10/12/2009 97,134 1,871,600 5.19%

10/9/2009 169,839 2,386,700 7.12%

10/8/2009 48,343 1,026,900 4.71%

10/7/2009 10,300 149,000 6.91%

10/6/2009 3,300 220,100 1.50%

10/5/2009 52,205 552,100 9.46%

10/2/2009 13,093 372,300 3.52%

10/1/2009 7,088 781,200 0.91%

9/30/2009 3,980 498,000 0.80%

9/29/2009 27,346 258,300 10.59%

9/28/2009 7,452 347,400 2.15%

9/25/2009 631 162,600 0.39%

9/24/2009 1,456 238,300 0.61%

9/23/2009 300 67,200 0.45%

9/22/2009 505 180,000 0.28%

9/21/2009 963 85,800 1.12%

9/18/2009 1,100 357,400 0.31%

9/17/2009 1,150 134,900 0.85%

9/16/2009 1,902 105,200 1.81%

9/15/2009 20,813 287,800 7.23%

9/14/2009 51,889 740,800 7.00%

9/11/2009 3,763 63,500 5.93%

9/10/2009 7,594 294,200 2.58%

9/9/2009 1,500 74,100 2.02%

9/8/2009 1,900 71,600 2.65%

9/4/2009 2,300 135,300 1.70%

9/3/2009 4,614 93,500 4.93%

9/2/2009 13,079 142,900 9.15%

9/1/2009 7,500 94,400 7.94%

8/31/2009 1,300 85,500 1.52%

8/28/2009 19,652 135,200 14.54%

8/27/2009 5,399 79,200 6.82%

8/26/2009 2,100 93,100 2.26%

8/25/2009 30,181 298,300 10.12%

8/24/2009 100 33,500 0.30%

8/21/2009 24,262 177,600 13.66%

8/20/2009 0 72,900 0.00%

8/19/2009 10,107 63,100 16.02%

8/18/2009 6,634 59,600 11.13%

8/17/2009 900 63,500 1.42%

8/14/2009 2,100 41,500 5.06%

8/13/2009 3,662 65,900 5.56%

8/12/2009 400 73,300 0.55%

8/11/2009 5,886 54,000 10.90%

8/10/2009 548 27,400 2.00%

8/7/2009 1,734 43,300 4.00%

8/6/2009 3,700 73,800 5.01%

8/5/2009 1,205 81,400 1.48%

8/4/2009 2,650 119,400 2.22%

8/3/2009 9,500 103,800 9.15%

Total 1,405,527 26,798,400 5.24%

In late October 2008 the SEC updated Regulation SHO requiring that all short sellers must locate, borrow and deliver any shares they have shorted, no exceptions, by T+3 settlement date. If not, a buy-in must be forced by the broker dealer that the short seller transacted through by the opening of the market on T+4. Since a company first appears on the naked short list when short sellers have been failing to deliver for 5 consecutive trading days, stocks should theoretically never be on the naked short list again. BUYINS.NET will monitor the exchangesai naked short lists daily and issue an alert and notify the SEC and FINRA should short sellers fail to deliver on any short sales.

Reg SHO Rule 204 (i) requires brokers to deliver shares on long and short sales of publicly traded equity securities by settlement date, (ii) continues to require brokers to close-out fails to deliver by the beginning of trading on T+4 for short sales and T+6 for long sales, (iii) precludes clearing brokers and their introducing brokers from selling short a security, other than on a pre-borrowed basis, if a fail to deliver in that security is not timely closed out until the fail is closed out and that close-out transaction settles, (iv) allows clearing brokers to allocate fails to introducing brokers and (v) continues to permit brokers to rely upon pre-fail credit to satisfy Rule 204's close-out requirement to avoid the pre-borrow requirements when a fail at a clearing broker has not been closed out. However, the SEC liberalized certain of these provisions in several regards. For example, permanent Rule 204 now allows a broker to close-out a fail on a long sale by borrowing the security, whereas Rule 204T had only permitted closing out long fails by buying-in, which should alleviate some of the buy-in risk for investors that experience long fails. Similar relief was extended to close-outs for market maker fails, so that a fail from a bona fide market making transaction (including short and long fails) can now be closed out by the beginning of trading on T+6 by borrowing the security. Further, Rule 204 now permits a broker to borrow securities to obtain pre-fail credit for early close-outs, whereas temporary Rule 204T only permitted pre-fail credit to be obtained by purchases of securities.

The SEC refused requests to extend the close-out deadline for fails to deliver to the close of business on the close-out deadline, choosing instead to retain the requirement that all fails be closed out by the beginning of trading on the applicable close-out deadline. The Commission also rejected requests for a fail to deliver exception that would have provided an exception from the close-out requirements if a clearing broker's fail position was below a certain amount but said that it would continue to monitor whether a de minimis or odd lot exception could be warranted.

Cardium Therapeutics, Inc. (AMEX: CXM) focuses on the acquisition and development of innovative bio-medical product opportunities and businesses that have the potential to address unmet medical needs and definable pathways to commercialization, partnering, and other economic monetizations. The companyais investment portfolio includes the Tissue Repair Company and Cardium Biologics, which are medical technology companies primarily focused on the development of innovative therapeutic products for tissue repair and cardiovascular indications. Its products include Generx, a DNA-based growth factor therapeutic that is in Phase III clinical stage designed to leverage the bodyais natural healing processes in response to repeated ischemic stress; Corgentin, a pre-clinical stage product, which enhances myocardial healing in and around the infarct zone when used as an adjunct to existing vascular-directed pharmacologic and interventional therapies; and Excellarate, a tissue repairais product candidate that is in Phase IIb clinical trial for the treatment of non-healing diabetic foot ulcers. The company was founded in 2003 and is headquartered in San Diego, California.

About BUYINS.NET

WWW.BUYINS.NET is a service designed to help bonafide shareholders of publicly traded US companies fight naked short selling. Naked short selling is the illegal act of short selling a stock when no affirmative determination has been made to locate shares of the stock to hypothecate in connection with the short sale. Buyins.net has built a proprietary database that uses Threshold list feeds from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the naked short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted and naked shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short and naked short trades.

BUYINS.NET has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2,650,000,000 short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like Buyins.net to access the data.

The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each monthais short transactions, BUYINS.NET provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.

All material herein was prepared by BUYINS.NET, based upon information believed to be reliable. The information contained herein is not guaranteed by BUYINS.NET to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. Occassionally companies or third parties pay $995 per month to purchase data for information provided in monthly reports. The data service can be cancelled at any time. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. BUYINS.NET is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. BUYINS.NET will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

BUYINS.NET and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of BUYINS.NET, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor. By visiting BUYINS.NET or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. BUYINS.NET, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to BUYINS.NET and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State. Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. BUYINS.NET does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. BUYINS.NET places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.

Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BUYINS.NET undertakes no obligation to update such statements.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.

Contact: Thomas Ronk, CEO www.BUYINS.net +1-800-715-9999 Tom@buyins.net